Warnex, the Montreal Heart Institute (MHI) and the Centre of Excellence in Personalized Medicine (Cepmed) are developing a test for the early detection of cardiovascular and metabolic diseases.
It is hoped that this test will enable the more personalised treatment of diseases such as atherosclerosis and diabetes.
Financed in part by Cepmed, the test will be developed by Warnex in collaboration with Dr Eric Thorin, a researcher at the MHI.
The diagnostic test to be developed is an enzyme-linked immunosorbent assay (Elisa) for detecting angiopoietin-like protein 2 (Angptl2) in blood.
Angptl2 stimulates the formation of new blood vessels, provokes inflammation and is elevated in the blood of patients with cardiovascular disease.
According to Thorin, this project could give rise to complementary research projects and could, therefore, help to advance research in cardiovascular diseases.
